C32 - Cell Line (ID:50112)
| HMS LINCS ID: | 50112 |
| Name: | C32 |
| Alternative Names: | |
| LINCS ID: | LCL-1238 |
| Alternative ID: | CLO_0002113 |
| Parent Cell Line: | |
| Reference Source: | ATCC CRL-1585 |
| Organism: | Homo sapiens |
| Organ: | skin |
| Tissue: | |
| Cell Type: | |
| Details of Cell Type: | |
| Donor Sex: | male |
| Donor Age: | |
| Donor Ethnicity: | |
| Donor Health Status: | |
| Disease: | DOID:1909, malignant melanoma |
| Details of Disease: | |
| Production Details: | |
| Genetic Modification(s): | none |
| Known Mutations: | |
| Citation Information for Mutations: | COSS906830 |
| Verification Reference Profile: | |
| Growth Properties: | adherent |
| Recommended Culture Conditions: | From MGH/CMT as specified by cell provider: Minimum essential medium (Eagle) with 2 mM L-glutamine and Earle's BSS adjusted to contain 1.5 g/L sodium bicarbonate, 0.1 mM non-essential amino acids, and 1.0 mM sodium pyruvate, 90%; fetal bovine serum, 10% |
| Relevant Citations: | |
| Usage Note: | |
| Comments: | |
| Date Publicly Available: | 2012-07-31 |
| Most Recent Update: | 2016-04-04 |
Batch Information for HMSL50112-1:
| HMS LINCS Batch ID: | 50112-1 |
| Provider: | Nathan Moerke (Harvard Medical School) |
| Provider Catalog ID: | |
| Provider Batch ID: | |
| Source Information: | Obtained by Nathan Moerke (Harvard Medical School) from the Center for Molecular Therapeutics (CMT; Massachusetts General Hospital) (contact: Cyril Benes) and distributed to Mohammad Fallahi-Sichani in 2012 |
| Date Received: | 2012 |
| HMS QC Outcome: | |
| Transient Modification(s): | |
| Comments: | |
| Date Publicly Available: | 2012-07-31 |
| Most Recent Update: | 2015-06-29 |